Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gut hormones may control blood flow to bones, new study hints

NCT ID NCT07679516

Knowledge-focused Sponsor: University of Copenhagen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 01, 2026 · Last updated Jul 10, 2026 · Updated 3 times

Summary

This study investigates whether natural gut hormones—GIP, GLP-2, and amylin—can change how much blood flows to the bones. Fifteen healthy adults aged 25 to 50 will receive infusions of each hormone separately, and a placebo, while researchers measure bone blood flow using advanced imaging. The goal is to understand basic bone physiology, which could eventually inform treatments for bone conditions like osteoporosis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
GIP, GLP-2, and amylin (as infusions)
What this could lead to
If these hormones are found to regulate bone blood flow, it could point toward new ways to treat or prevent bone diseases like osteoporosis.
What could go wrong
This is a very small, early study in healthy people, so results may not apply to those with bone conditions. It only measures short-term effects, not long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 15 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 to 50 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 25-50 years. 2. BMI between 18.5-30 kg/m2. 3. Normal gait. 4. Premenopausal (if female). 5. Informed consent. Exclusion Criteria: 1. Bone disease incl. confirmed osteopenia. 2. Fracture within the last 6 months at the time of inclusion. 3. Amputation or congenital defect of extremities. 4. HbA1c\>41.9 mmol/mol and/or diagnosed type 1 or type 2 diabetes. 5. Any ongoing or prior medication that the investigator evaluates could interfere with the endpoints of the study (e.g. glucocorticoids or other medications that may compromise bone health). 6. Pregnancy or breastfeeding (or plans thereof within the study duration). 7. Not using effective hormonal contraceptives or an intra uterine device within study duration (e.g. oral contraceptives, transdermal patch, vaginal ring, Depo-Provera injections, Nexplanon implant). 8. Ongoing or prior alcohol abuse (defined per ICD-10 classification for alcohol dependence syndrome, F10.21) or daily alcohol intake 9. Use of any illicit substance or narcotics within three months of inclusion, including within study duration. 10. Any physical or psychological condition that the investigator evaluates would interfere with trial participation. 11. Recent (three months prior to inclusion), ongoing or planned weight loss within study duration (weight loss defined as exceeding -5% bodyweight, or intentional hypocaloric dieting)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYLIN are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AMYLIN Bone blood flow regulation Bone physiology GIP GLP-2 Gut hormones Healthy adult participants Peptide hormones

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Rigshospitalet

    Copenhagen, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.